SPS
VERV

Susquehanna Portfolio Strategies’s Verve Therapeutics VERV Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,300
Closed -$149K – 1112
2025
Q2 		$149K Buy
+13,300
New +$75.8K ﹤0.01% 808

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Susquehanna Portfolio Strategies's VERV Position: Q3 2025 in Review

Susquehanna Portfolio Strategies sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 13,300 shares — an estimated $149K sold.

Susquehanna Portfolio Strategies first reported a position in VERV in Q2 2025 and held it in 1 quarter. The position peaked at $149K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Susquehanna Portfolio Strategies reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 13,300 Verve Therapeutics shares in Q3 2025, an estimated $149K.
  • Susquehanna Portfolio Strategies first reported a position in Verve Therapeutics in Q2 2025 and held it in 1 quarter.
  • Susquehanna Portfolio Strategies's Verve Therapeutics position peaked at $149K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Susquehanna Portfolio Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.